For head and neck cancers, these include epidermal growth factor receptor (EGFR) inhibitors and immune checkpoint inhibitors targeting programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1). Here, EGFR is linked to head and neck cancer.